Skip to main content

Table 2 Abundance of 12 N-glycan structures attached to serum proteins in IgD MM, LCMM patients and healthy CTRs

From: N-glycosylation of serum proteins for the assessment of patients with IgD multiple myeloma

Structures Healthy CTR IgD MM LCMM P1 P2
(n = 42) (κ 1, λ 19) (κ 19, λ 22)
NGA2F 7.79 ± 1.94 5.77 ± 2.04 6.93 ± 3.00 <0.001 NS
NGA2FB 1.30 ± 0.45 1.06 ± 0.80 0.90 ± 0.54 NS NS
NG1(6)A2F 6.32 ± 1.11 3.17 ± 1.09 3.44 ± 1.40 <0.001 NS
NG1(3)A2F 5.61 ± 1.22 3.53 ± 0.97 4.15 ± 0.84 <0.001 0.013
NA2 38.76 ± 3.06 44.07 ± 6.20 47.49 ± 6.43 0.001 NS
NA2F 20.14 ± 2.54 18.50 ± 9.56 14.76 ± 5.63 NS NS
NA2FB 6.21 ± 1.40 4.85 ± 3.37 2.52 ± 2.40 NS 0.009
NA3 7.80 ± 1.96 9.84 ± 3.26 10.08 ± 3.51 0.016 NS
NA3Fb 2.68 ± 1.28 4.57 ± 3.14 5.04 ± 3.21 0.017 NS
NA3F2 0.34 ± 0.13 0.42 ± 0.16 0.46 ± 0.23 0.035 NS
NA4 1.69 ± 0.61 2.97 ± 0.95 3.01 ± 1.36 <0.001 NS
NA4Fb 0.47 ± 0.24 1.25 ± 0.89 1.22 ± 0.73 0.001 NS
  1. Note: Quantitative data are expressed as the means ± standard deviation; P1: comparison between IgD MM patients and healthy CTR
  2. P2: comparison between IgD MM and LCMM patients
  3. Abbreviations: IgD MM IgD multiple myeloma, LCMM light chain multiple myeloma, CTR control subject, NS non-significant